Effect of basic fibroblast growth factor treatment on brain progenitor cells after permanent focal ischemia in rats.
OBJECTIVE
Intracisternal basic fibroblast growth factor (bFGF) enhances sensorimotor recovery after focal cerebral infarction in rats. One possible mechanism is stimulation of endogenous progenitor cells in brain. We investigated the effects of intracisternal bFGF on brain progenitor cells after stroke.


METHODS
Proliferating brain cells were labeled with bromodeoxyuridine (BrdU) before middle cerebral artery (MCA) occlusion or sham surgery in rats. bFGF (0.5 microg) or vehicle was administered intracisternally at 24 and 48 hours after MCA occlusion, and rats were killed at 7, 14, or 21 days after stroke. Immunohistochemistry for BrdU and neuron- or astrocyte-specific markers was used to characterize progenitor cells and their progeny in the subventricular zone and dentate gyrus of the hippocampus.


RESULTS
Infarct size did not differ among rats with or without bFGF treatment. MCA occlusion alone increased the number of BrdU-labeled cells in the ipsilateral subventricular zone at days 7 to 21, and there was a trend toward increased cell proliferation with bFGF treatment. In the dentate gyrus, the number of BrdU-labeled cells was increased bilaterally after MCA occlusion (peak at day 7). This increase was greater after bFGF treatment. In the subventricular zone, 30% of BrdU-labeled cells were immunopositive for the immature neuron-specific marker doublecortin at day 7, and their number declined to 2% at day 21. In the dentate gyrus, the majority of BrdU-labeled cells colabeled with doublecortin at day 7, becoming NeuN positive at day 21.


CONCLUSIONS
Stroke produces significant changes in progenitor cells in brain that are augmented by bFGF treatment.
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Mass, USA.
Kuniyasu
K
Wada
Hiroshi
H
Sugimori
Pradeep G
PG
Bhide
Michael A
MA
Moskowitz
Seth P
SP
Finklestein
D000818:Animals; D000943:Antigens, Differentiation / Q000096:biosynthesis; D001921:Brain / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology; D002545:Brain Ischemia / Q000188:drug therapy* / Q000473:pathology; D001973:Bromodeoxyuridine; D002452:Cell Count; D018891:Dentate Gyrus / Q000187:drug effects / Q000473:pathology; D004195:Disease Models, Animal; D018450:Disease Progression; D000089662:Doublecortin Protein; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D007150:Immunohistochemistry; D007276:Injections, Intraventricular; D020547:Lateral Ventricles / Q000187:drug effects / Q000473:pathology; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013234:Stem Cells / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
D000943:Antigens, Differentiation; C000714848:Dcx protein, rat; D000089662:Doublecortin Protein; D016222:Fibroblast Growth Factor 2; D001973:Bromodeoxyuridine